These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 18951790)

  • 1. SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
    Methot JL; Hamblett CL; Mampreian DM; Jung J; Harsch A; Szewczak AA; Dahlberg WK; Middleton RE; Hughes B; Fleming JC; Wang H; Kral AM; Ozerova N; Cruz JC; Haines B; Chenard M; Kenific CM; Secrist JP; Miller TA
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6104-9. PubMed ID: 18951790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenylglycine and phenylalanine derivatives as potent and selective HDAC1 inhibitors (SHI-1).
    Wilson KJ; Witter DJ; Grimm JB; Siliphaivanh P; Otte KM; Kral AM; Fleming JC; Harsch A; Hamill JE; Cruz JC; Chenard M; Szewczak AA; Middleton RE; Hughes BL; Dahlberg WK; Secrist JP; Miller TA
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1859-63. PubMed ID: 18304810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors.
    Thaler F; Varasi M; Abate A; Carenzi G; Colombo A; Bigogno C; Boggio R; Zuffo RD; Rapetti D; Resconi A; Regalia N; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C
    Eur J Med Chem; 2013 Jun; 64():273-84. PubMed ID: 23644210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
    Li X; Zhang Y; Jiang Y; Wu J; Inks ES; Chou CJ; Gao S; Hou J; Ding Q; Li J; Wang X; Huang Y; Xu W
    Eur J Med Chem; 2017 Jul; 134():185-206. PubMed ID: 28415009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.
    Marson CM; Matthews CJ; Yiannaki E; Atkinson SJ; Soden PE; Shukla L; Lamadema N; Thomas NS
    J Med Chem; 2013 Aug; 56(15):6156-74. PubMed ID: 23829483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
    Shultz MD; Cao X; Chen CH; Cho YS; Davis NR; Eckman J; Fan J; Fekete A; Firestone B; Flynn J; Green J; Growney JD; Holmqvist M; Hsu M; Jansson D; Jiang L; Kwon P; Liu G; Lombardo F; Lu Q; Majumdar D; Meta C; Perez L; Pu M; Ramsey T; Remiszewski S; Skolnik S; Traebert M; Urban L; Uttamsingh V; Wang P; Whitebread S; Whitehead L; Yan-Neale Y; Yao YM; Zhou L; Atadja P
    J Med Chem; 2011 Jul; 54(13):4752-72. PubMed ID: 21650221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches.
    Adhikari N; Amin SA; Trivedi P; Jha T; Ghosh B
    Eur J Med Chem; 2018 Sep; 157():1127-1142. PubMed ID: 30179749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).
    Methot JL; Chakravarty PK; Chenard M; Close J; Cruz JC; Dahlberg WK; Fleming J; Hamblett CL; Hamill JE; Harrington P; Harsch A; Heidebrecht R; Hughes B; Jung J; Kenific CM; Kral AM; Meinke PT; Middleton RE; Ozerova N; Sloman DL; Stanton MG; Szewczak AA; Tyagarajan S; Witter DJ; Secrist JP; Miller TA
    Bioorg Med Chem Lett; 2008 Feb; 18(3):973-8. PubMed ID: 18182289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.
    Moradei OM; Mallais TC; Frechette S; Paquin I; Tessier PE; Leit SM; Fournel M; Bonfils C; Trachy-Bourget MC; Liu J; Yan TP; Lu AH; Rahil J; Wang J; Lefebvre S; Li Z; Vaisburg AF; Besterman JM
    J Med Chem; 2007 Nov; 50(23):5543-6. PubMed ID: 17941625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells.
    Liu YM; Lee HY; Lai MJ; Pan SL; Huang HL; Kuo FC; Chen MC; Liou JP
    Org Biomol Chem; 2015 Oct; 13(40):10226-35. PubMed ID: 26309122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity.
    Ibrahim HS; Abdelsalam M; Zeyn Y; Zessin M; Mustafa AM; Fischer MA; Zeyen P; Sun P; Bülbül EF; Vecchio A; Erdmann F; Schmidt M; Robaa D; Barinka C; Romier C; Schutkowski M; Krämer OH; Sippl W
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parallel medicinal chemistry approaches to selective HDAC1/HDAC2 inhibitor (SHI-1:2) optimization.
    Kattar SD; Surdi LM; Zabierek A; Methot JL; Middleton RE; Hughes B; Szewczak AA; Dahlberg WK; Kral AM; Ozerova N; Fleming JC; Wang H; Secrist P; Harsch A; Hamill JE; Cruz JC; Kenific CM; Chenard M; Miller TA; Berk SC; Tempest P
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1168-72. PubMed ID: 19138845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-(Heteroarylaminomethyl)-N-(2-aminophenyl)-benzamides and their analogs as a novel class of histone deacetylase inhibitors.
    Fréchette S; Leit S; Woo SH; Lapointe G; Jeannotte G; Moradei O; Paquin I; Bouchain G; Raeppel S; Gaudette F; Zhou N; Vaisburg A; Fournel M; Yan PT; Trachy-Bourget MC; Kalita A; Robert MF; Lu A; Rahil J; Robert Macleod A; Besterman JM; Li Z; Delorme D
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1502-6. PubMed ID: 18207391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and semisynthesis of novel fredericamycin A derivatives with an improved antitumor profile.
    Abel U; Simon W; Eckard P; Hansske FG
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3292-7. PubMed ID: 16621542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases.
    Lee HY; Wang LT; Li YH; Pan SL; Chen YL; Teng CM; Liou JP
    Org Biomol Chem; 2014 Nov; 12(44):8966-76. PubMed ID: 25277250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and antiproliferative activities of novel benzamides derivatives as HDAC inhibitors.
    Li Y; Wang Y; Xie N; Xu M; Qian P; Zhao Y; Li S
    Eur J Med Chem; 2015 Jul; 100():270-6. PubMed ID: 26140961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel.
    Dinges J; Albert DH; Arnold LD; Ashworth KL; Akritopoulou-Zanze I; Bousquet PF; Bouska JJ; Cunha GA; Davidsen SK; Diaz GJ; Djuric SW; Gasiecki AF; Gintant GA; Gracias VJ; Harris CM; Houseman KA; Hutchins CW; Johnson EF; Li H; Marcotte PA; Martin RL; Michaelides MR; Nyein M; Sowin TJ; Su Z; Tapang PH; Xia Z; Zhang HQ
    J Med Chem; 2007 May; 50(9):2011-29. PubMed ID: 17425296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and docking studies on benzamide derivatives as histone deacetylase inhibitors.
    Lu A; Luo H; Shi M; Wu G; Yuan Y; Liu J; Tang F
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4924-7. PubMed ID: 21741834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of 4-[(s-triazin-2-ylamino)methyl]-N-(2-aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitors.
    Paquin I; Raeppel S; Leit S; Gaudette F; Zhou N; Moradei O; Saavedra O; Bernstein N; Raeppel F; Bouchain G; Fréchette S; Woo SH; Vaisburg A; Fournel M; Kalita A; Robert MF; Lu A; Trachy-Bourget MC; Yan PT; Liu J; Rahil J; MacLeod AR; Besterman JM; Li Z; Delorme D
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1067-71. PubMed ID: 18160287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
    Witter DJ; Harrington P; Wilson KJ; Chenard M; Fleming JC; Haines B; Kral AM; Secrist JP; Miller TA
    Bioorg Med Chem Lett; 2008 Jan; 18(2):726-31. PubMed ID: 18060775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.